Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C

Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C

Background: Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinica...

Full description

Bibliographic Details
Main Authors: Elif Sargin Altunok, Murat Sayan, Sila Akhan, Bilgehan Aygen, Orhan Yildiz, Suda Tekin Koruk, Resit Mistik, Nese Demirturk, Onur Ural, Şükran Kose, Aynur Aynioglu, Fatime Korkmaz, Gülden Ersoz, Nazan Tuna, Celal Ayaz, Faruk Karakecili, Derya Keten, Dilara Inan, Saadet Yazici, Safiye Koculu, Taner Yildirmak
Format: Article
Language:English
Published: Elsevier 2016-09-01
Series:International Journal of Infectious Diseases
Subjects:
Baseline resistance
hepatitis C virus
mutation
protease inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971216311109

Internet

http://www.sciencedirect.com/science/article/pii/S1201971216311109

Similar Items